ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

abrysvo

Also written as “RSVpreF”, “RSVpreF Vaccine” and “RSVpreF (Regimen A)”.

Its studies are mostly in Respiratory Tract Infections · Respiratory Syncytial Virus Infections · COVID-19 · Influenza, Human, led by 2 companies.

Drug pageAbrysvo: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 3, 202018 company-led studies, 7 open or runningNext primary completion: Jan 18, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only177 open or runningphase 3since Jun 3, 2020Jun 3, 2020Jan 18, 2027phase 3 · NCT05035212
Hvivo10 open or runningphase 2since Feb 12, 2021Feb 12, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hvivo only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 12, 2021First study: phase 2 study in Respiratory Syncytial Virus InfectionsFirst studyNCT04785612 · 70 enrolled · United Kingdom

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Fusion glycoprotein F0 vaccine antigen”ChEMBL 37, by rule

Studies

The one study Hvivo leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04785612Respiratory Syncytial Virus Infections · United Kingdom2CompletedApr 8, 202170

How it is read

Names in the registry

  • “RSVpreF”, 10 entries
  • “RSVpreF Vaccine”, 2 entries
  • “RSVpreF (Regimen A)”, 1 entry
  • “RSVpreF (Regimen B)”, 1 entry
  • “RSVpreF vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.